Cell and Gene Therapy CDMO Services Market

The cell and gene therapy CDMO services market is worth USD 6,076.0 million in 2025 and reaches USD 23,377.4 million by 2035, compounding at 14.42% a year. The figure is built bottom-up: roughly 9,800 cell and gene therapy manufacturing batches produced by contract development and manufacturing organisations in 2025 across viral vector lots, cell therapy patient and allogeneic lots, plasmid DNA and messenger RNA starting materials, and associated process development, analytics and fill finish, at an average realised revenue of USD 620,000 per batch, triangulated against clinical trial activity, approved product volumes and CDMO disclosures. Batches grow 12.4% a year as therapies advance through the clinic and approved products scale, while revenue per batch rises 1.8% a year as later stage and commercial work carries higher value. This study sits within our pharmaceutical manufacturing services coverage and follows the published Douglas Insights methodology.

What happened when the capacity boom met the funding bust?

A painful correction that the sector is still working through, and one that shapes the outlook more than any headline growth rate. During the period of abundant biotechnology funding, investors poured money into cell and gene therapy developers, and contract manufacturers raced to build capacity for viral vectors and cell therapy production, expecting a flood of programmes to move into late stage trials and commercial supply. Then biotechnology funding contracted sharply, many developers cut programmes or shut down, and clinical progress for several therapies proved slower and more difficult than hoped. The result was significant excess capacity, particularly in viral vector manufacturing, with CDMOs reporting underused facilities, layoffs, site closures and consolidation. At the same time, the science kept advancing: cell therapies for blood cancers moved into earlier treatment lines, the first gene editing therapy was approved for sickle cell disease, and new approvals continued. The outlook therefore combines genuine long term growth with a near term period in which demand is catching up to capacity built for a faster future. The exclusive chapter of this report tracks capacity against demand by modality, because utilisation, not headline growth, determines CDMO profitability.

What does this market include?

This study covers contract development and manufacturing services for cell and gene therapies. Viral vector manufacturing covers production of adeno associated virus, lentivirus and other viral vectors used to deliver genes, the largest and most capital intensive service. Cell therapy manufacturing covers manufacture of autologous therapies made from each patient’s own cells, such as chimeric antigen receptor T cell therapies, and allogeneic therapies made from donor cells. Plasmid DNA and messenger RNA starting materials cover production of plasmids used to make viral vectors and other starting materials. Process development, analytics and fill finish cover development of manufacturing processes, analytical testing and release, and final filling of products. In house manufacturing by therapy developers, conventional biologics and small molecule contract manufacturing, gene editing tools sold as reagents, and equipment and consumables sold to manufacturers sit outside the boundary. Value is measured at revenue earned by CDMOs.

Why is making these therapies so hard?

Because they are living or biological products whose manufacturing is complex, variable and difficult to scale, unlike conventional drugs. Viral vectors are produced in cells that are engineered to make virus particles, then purified, and yields are often low, processes are variable, and quality testing is extensive, which makes vectors expensive and production capacity a constraint. Autologous cell therapies are even more demanding: each dose is made individually for one patient, starting from that patient’s cells, which must be collected, shipped to a manufacturing site, modified and expanded over weeks, tested and shipped back, with the chain of identity maintained throughout, since giving the wrong patient’s cells would be dangerous. This patient by patient model does not scale like conventional manufacturing, and failures or delays directly affect sick patients. Allogeneic therapies made from donor cells promise more scalable, off the shelf production but remain earlier in development. These challenges explain why many developers outsource to CDMOs with specialised expertise and facilities, why manufacturing costs are a large share of therapy prices, and why improving manufacturing efficiency is central to broadening access.

What drives demand?

The first driver is approvals and label expansions. New approvals and the movement of existing therapies into earlier treatment lines increase commercial manufacturing volume.

The second driver is the clinical pipeline. Hundreds of cell and gene therapy programmes are in clinical development, each requiring manufacturing for trials, and many developers lack their own facilities.

The third driver is outsourcing. Building in house cell and gene therapy manufacturing is expensive and slow, so most smaller developers and many larger ones outsource to CDMOs.

The fourth driver is new modalities and indications. Gene editing, in vivo gene therapy and cell therapies for autoimmune diseases and solid tumours extend demand beyond the initial blood cancer and rare disease applications.

What restrains the market?

Three restraints are modelled. Biotechnology funding is the first and most immediate: cell and gene therapy developers depend on investor funding, and the downturn cut programmes and delayed trials, directly reducing CDMO demand. Excess capacity is second: capacity built during the boom, particularly for viral vectors, exceeds near term demand, pressuring pricing and utilisation. Clinical and commercial risk is third: therapies may fail in trials, face safety concerns, or struggle commercially because of high prices, complex administration and reimbursement challenges, which limits volume even after approval.

Which services carry the revenue?

Viral vector manufacturing leads with 42% of 2025 revenue, USD 2,551.9 million, the largest and most capital intensive service, needed for gene therapies and many cell therapies. Cell therapy manufacturing holds 30%, USD 1,822.8 million, and grows fastest as approved cell therapies scale and new indications emerge. Plasmid DNA and messenger RNA starting materials account for 14%, USD 850.6 million, essential inputs to vector production. Process development, analytics and fill finish contribute 14%, USD 850.6 million. Each service is modelled through 2035 by modality and region.

Where is CDMO capacity concentrated?

North America leads with 50% of 2025 revenue, USD 3,038.0 million, growing 13.6% a year, reflecting the concentration of cell and gene therapy developers, approvals and CDMO capacity in the United States. Europe holds 28%, USD 1,701.3 million, at 14.2%, with strong capacity in the United Kingdom, Germany, France and elsewhere. Asia Pacific holds 18%, USD 1,093.7 million, and grows fastest at 16.8%, driven by China’s large cell therapy development sector, South Korean and Japanese CDMOs, and cost competitive capacity, affected by supply chain policies in the United States. The Middle East contributes USD 121.5 million at 15.0%, Latin America USD 85.1 million at 13.6% and Africa USD 36.5 million at 12.0%. Six regional models sum to the global figure, with country tables in the Excel model.

Who provides cell and gene therapy CDMO services?

Lonza is one of the largest cell and gene therapy CDMOs, with capacity for viral vectors and cell therapies. Thermo Fisher Scientific, Charles River Laboratories, Catalent, now part of Novo Holdings, and Fujifilm Diosynth offer cell and gene therapy manufacturing, and specialists including Oxford Biomedica, AGC Biologics, Genezen, Andelyn and Minaris, among others, focus on the segment. WuXi and other Chinese CDMOs have been significant, though affected by United States policy on Chinese biotechnology suppliers. The sector has seen consolidation, facility sales and closures following the funding downturn. The competitive chapter profiles each CDMO’s modality coverage, capacity and utilisation, regulatory track record and commercial product experience.

How are CDMO services priced?

Average realised revenue is USD 620,000 per batch in 2025, varying enormously by modality and stage. A clinical viral vector batch may cost from several hundred thousand to over a million dollars, a commercial scale vector batch more, and autologous cell therapy manufacturing is priced per patient dose, typically in the tens to hundreds of thousands of dollars. Process development and technology transfer are charged separately and can be substantial. Pricing has come under pressure from excess capacity in viral vectors, while demand for experienced commercial cell therapy manufacturing supports pricing in that segment. As more programmes move from clinical to commercial stages, which carry higher value, revenue per batch rises modestly. The pricing chapter publishes price bands by modality and stage.

How do the scenarios diverge by 2035?

The base case carries 12.4% growth in batches and 1.8% growth in revenue per batch for a 14.42% revenue CAGR and USD 23,377.4 million in 2035. The prolonged-downturn scenario, in which funding stays weak, pipelines shrink and excess capacity persists, sets the legs at 7.6% and minus 1.0%, landing near USD 11,340 million. The approval-wave scenario, in which multiple therapies are approved for large indications, allogeneic and in vivo approaches scale and funding recovers, sets them at 15.8% and 3.2%, carrying the market past USD 36,000 million. Each 1-point change in batch growth moves the 2035 figure by roughly USD 2,080 million.

Which rules and standards apply?

Three layers matter. Advanced therapy regulation comes first: cell and gene therapies are regulated as advanced therapy medicinal products or biologics, with manufacturing held to good manufacturing practice and specific requirements for these products, and regulators inspect CDMO facilities that manufacture them. Chain of identity and custody requirements are second, particularly for autologous therapies, where regulations require rigorous tracking to ensure each patient receives their own cells. Supply chain and foreign supplier policy is third: United States legislation and policy concerning certain foreign biotechnology suppliers have prompted developers to review manufacturing partners, affecting the geographic distribution of CDMO work. The regulatory chapter maps these requirements by jurisdiction.

Can manufacturing costs come down enough to broaden access?

The high cost of manufacturing cell and gene therapies is a central reason they are so expensive, often priced in the hundreds of thousands to millions of dollars per patient, and reducing that cost is essential if these therapies are to reach larger patient populations. Several approaches are being pursued. Automated, closed manufacturing systems for cell therapy reduce labour, contamination risk and variability, allowing more doses per facility. Improved viral vector processes raise yields, cutting cost per dose. Allogeneic therapies made from donor cells could replace one batch per patient with one batch serving many patients, transforming the economics if they prove effective. And in vivo gene therapies and editing, delivered directly into the patient rather than modifying cells outside the body, could simplify manufacturing further. Each of these would change the volume and value mix for CDMOs: more automation and allogeneic production could increase the number of doses while lowering revenue per dose. The model reflects gradual efficiency gains that support volume growth while moderating price growth.

Douglas Exclusive: the capacity and utilisation tracker

This report tracks, by modality and CDMO, installed manufacturing capacity, utilisation, planned expansions and closures, and projected demand from clinical and commercial programmes, identifying where capacity exceeds or falls short of demand and converting pipeline and approval forecasts into batches and revenue by service and region. Licence holders receive it as a maintained tab in the Excel model.

Methodology and receipts

The model is built bottom-up from batches: clinical programmes by modality and phase, approved products and patient volumes, outsourcing share, batches per programme and per patient, and realised revenue per batch from CDMO disclosures, with in house manufacturing, conventional biologics and small molecule CDMO work, reagents and equipment excluded. Every figure carries a numbered source and a confidence grade in the fact sheet above, and the working model ships with every licence. The next scheduled review of this study is September 2027.